HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Hepatitis B Antibodies

Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Also Known As:
Anti HBAg; Hepatitis B Virus Antibodies; Anti Australia Antigens; Anti Hepatitis B Antigens; Antibodies, Hepatitis B; Antigens, Anti-Australia; Antigens, Anti-Hepatitis B; B Antibodies, Hepatitis; B Antigens, Anti-Hepatitis; HBAg, Anti; Anti-Australia Antigens; Anti-HBAg; Anti-Hepatitis B Antigens
Networked: 31 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Beyaz, Mustafa: 1 article (10/2014)
2. Basaran, Michael M: 1 article (10/2014)
3. Raupach, Regina: 1 article (10/2014)
4. Wedemeyer, Heiner: 1 article (10/2014)
5. Bremer, Birgit: 1 article (10/2014)
6. Stahmeyer, Jona T: 1 article (10/2014)
7. Manns, Michael P: 1 article (10/2014)
8. Heidrich, Benjamin: 1 article (10/2014)
9. Bastürk, Murat: 1 article (10/2014)
10. Braynis, Boris: 1 article (10/2014)

Related Diseases

1. Hepatitis B
02/01/1988 - "The use of hepatitis B core antibody for screening and subsequent hepatitis B vaccination of antibody-negative personnel was most cost-effective for hospitals considered to have high prevalence for hepatitis B virus antibodies among its staff, although use of hepatitis B surface antibody in this setting only increased costs by 1.4%. "
02/01/1988 - "We concluded that hepatitis B core antibody should be used for screening in hospitals with high prevalence for hepatitis B virus antibodies among employees while hepatitis B surface antibody be used for screening in hospitals with low prevalence for hepatitis B virus antibodies among employees. "
02/01/1988 - "In a hospital with low prevalence for hepatitis B virus antibodies among its staff, use of hepatitis B surface antibody and subsequent vaccination of antibody-negative individuals was the most cost-effective approach, while use of hepatitis B core antibody for the above purposes would have increased costs by 3.4%. "
02/01/1988 - "We compared the cost of antibody screening and the projected cost for hepatitis B vaccination of antibody-negative individuals at hospitals with "high prevalence" and "low prevalence" rates for hepatitis B virus antibodies among their employees. "
04/16/1987 - "We conclude that hepatitis B caused the outbreak, that about 330,000 persons may have been infected, that the hepatitis B virus carrier state was a rare consequence, and that the outbreak induced hepatitis B antibodies that appear to persist for life."
2. Infection
3. Hepatitis A (Hepatitis, Infectious)
4. Hepatitis C
5. Hepatitis

Related Drugs and Biologics

1. Hepatitis B Surface Antigens (HBsAg)
2. Surface Antigens (Surface Antigen)
3. Antigens
4. Antibodies
5. RNA (Ribonucleic Acid)
6. Immunoglobulins (Immunoglobulin)
7. Immunoglobulin G (IgG)
8. gamma-Globulins (gamma-Globulin)
9. Hepatitis A Antibodies
10. Zinc Sulfate